APA (7th ed.) Citation

F, P., G, P., I, V., & A, L. (2022). Neoadjuvant or adjuvant immunotherapy in bladder cancer: Biological opportunity or clinical utility? Tumori, 108(5), 510. https://doi.org/10.1177/03008916211061604

Chicago Style (17th ed.) Citation

F, Petrelli, Perego G, Vavassori I, and Luciani A. "Neoadjuvant or Adjuvant Immunotherapy in Bladder Cancer: Biological Opportunity or Clinical Utility?" Tumori 108, no. 5 (2022): 510. https://doi.org/10.1177/03008916211061604.

MLA (9th ed.) Citation

F, Petrelli, et al. "Neoadjuvant or Adjuvant Immunotherapy in Bladder Cancer: Biological Opportunity or Clinical Utility?" Tumori, vol. 108, no. 5, 2022, p. 510, https://doi.org/10.1177/03008916211061604.